Challenges and guidelines for clinical trial of herbal drugs

Journal of Pharmacy and Bioallied Sciences

Volumn 7, Issue 4, 2015, Pages 329-333

  Parveen, Abida ^a   Parveen, Bushra ^b   Parveen, Rabea ^b   Ahmad, Sayeed ^b  

^a ESCORTS HEART INSTITUTE AND RESEARCH CENTRE   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Clinical trial; herbal drugs; regulatory guidelines

Indexed keywords

ACETAZOLAMIDE; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; NIPRISAN EXTRACT; REDUNING EXTRACT; TIANQI EXTRACT; TRIPTERYGIUM WILFORDII EXTRACT; UNCLASSIFIED DRUG;

ALTITUDE DISEASE; CHINA; CLINICAL RESEARCH; CONFERENCE PAPER; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GERMANY; GINGER; GOLD STANDARD; GOOD MANUFACTURING PRACTICE; HAND FOOT AND MOUTH DISEASE; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH SURVEY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; IMPAIRED GLUCOSE TOLERANCE; INDIA; IRRITABLE COLON; JAPAN; MASS FRAGMENTOGRAPHY; NIPRISAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOTHERAPY; PLACEBO EFFECT; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUNING; RHEUMATOID ARTHRITIS; SICKLE CELL ANEMIA; SOUTH KOREA; STANDARDIZATION; TIANQI; TRADITIONAL MEDICINE; TREATMENT DURATION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 84946038178     PISSN: None     EISSN: 09757406     Source Type: Journal    
DOI: 10.4103/0975-7406.168035     Document Type: Conference Paper

References (45)

1. Mills S. Herbal medicine. In: Lewith GT, Jonas WB, Walach H, editors. Clinical Research in Complementary Therapies: Principles, Problems and Solutions. Churchill, Livingstone: Elsevier Science; 2003. p. 211-27.
2. Bansal D, Hota D, Chakrabarti A. Research methodological issues in evaluating herbal interventions. J Clin Trial. 2010; 2: 15-21.
3. Kumar K. Fundamentals of Clinical Trials. USA: Howard University, USA in Collaboration with NIPRD, Abuja, Nigeria, and Xechem International Inc.; 2005. p. 178.
4. Lai SL. Clinical Trials of Traditional Chinese Materia Medica. Ch. 1. Guangdong: Peoples Publishing House; 2000.
5. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993; 328: 246-52.
6. US Food and Drug Administration. Guidance for Industry: Botanical drug products; 2004. Available from: http://www.fda.gov/downloads/.Drugs/GuidanceComplianceRegulatoryInformation/Guidances/.ucm070491.pdf. [Last accessed on 2014 Mar 22
7. World Health Organization. Operational Guidance: Information Needed to Support Clinical Trials of Herbal Products. (Document reference who/TDR/GEN/Guidance/05.1). Geneva, Switzerland: World Health Organization; 2005.
8. Leung PC. Complementary medicine. In: Machin D, Day S, Green S, editors. Textbook of Clinical Trials. 1st ed. Chichester: John Wiley and Sons; 2004. p. 63-84.
9. Jonas WB, Linde K. Conducting and evaluating clinical research on complementary and alternative medicine. In: Gallin JI, editor. Principles and Practice of Clinical Research. San Diego, CA: Academic Press; 2002. p. 401-26.
10. Ernst E, Siev-Ner I, Gamus D. Complementary medicine - A critical review. Isr J Med Sci. 1997; 33: 808-15.
11. Kleinman A, Eisenberg L, Good B. Culture, illness, and care: Clinical lessons from anthropologic and cross-cultural research. Ann Intern Med. 1978; 88: 251-8.
12. Richardson J. The use of randomized control trials in complementary therapies: Exploring the issues. J Adv Nurs. 2000; 32: 398-406.
13. Brewin CR, Bradley C. Patient preferences and randomised clinical trials. BMJ. 1989; 299: 313-5.
14. Walker LG, Anderson J. Testing complementary and alternative therapies within a research protocol. Eur J Cancer. 1999; 35: 1614-8.
15. Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: A double-blind placebo-controlled study. Phytother Res. 1997; 11: 508-11.
16. Buchanan DR, White JD, OMara AM, Kelaghan JW, Smith WB, Minasian LM. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: Lessons from the National Cancer Institute Community Clinical Oncology Program experience. J Clin Oncol. 2005; 23: 6682-9.
17. Critchley JA, Zhang Y, Suthisisang CC, Chan TY, Tomlinson B. Alternative therapies and medical science: Designing clinical trials of alternative/complementary medicines - Is evidence-based traditional Chinese medicine attainable? J Clin Pharmacol. 2000; 40: 462-7.
18. Bian ZX, Li YP, Moher D, Dagenais S, Liu L, Wu TX, et al. Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: Clinical trial design and methodology. Zhong Xi Yi Jie He Xue Bao. 2006; 4: 120-9.
19. Howard KI, Orlinsky DE, Perilstein J. Contribution of therapists to patients experiences in psychotherapy: A components of variance model for analyzing process data. J Consult Clin Psychol. 1976; 44: 520-6.
20. Mason S, Tovey P, Long AF. Evaluating complementary medicine: Methodological challenges of randomised controlled trials. BMJ. 2002; 325: 832-4.
21. Bower H. Double standards exist in judging traditional and alternative medicine. Br Med J. 1998; 316: 1694.
22. WHO. Traditional Medicine. WHO Fact Sheet No. 134. Available from: www.http://tinyurl.com/5mrd5. [Last accessed on 2014 Apr 23
23. BBC News. Can Herbal Medicine Combat Aids? Wednesday, 15 March, 2006, 13: 10 GMT. Available from: http://www. newsvote.bbc.co.uk/mpapps/pagetools/print/news.bbc.co.uk/2/hi/.Africa/4793106.stm. [Last accessed on 2013 Apr 16
24. Ameh SJ, Obodozie OO, Abubakar MS, Garba M. Current phytotherapy - An inter-regional perspective on policy, research and development of herbal medicine. J Med Plants Res. 2010; 4: 1508-16.
25. World Health Organization. Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines. Geneva: World Health Organization; 1993.
26. De Smet PA. Herbal remedies. N Engl J Med. 2002; 347: 2046-56.
27. Chadwick L, Fong H. Herb quality assurance and standardization in herb-drug interaction evaluation and documentation. In: Lam YW, Huang SM, Hall SD, editors. Herbal Supplement-Drug Interactions. New York: Taylor and Francis; 2006. p. 191-203.
28. World Health Organization. Regulatory Situation of Herbal Medicines. A Worldwide Review. Geneva: World Health Organization; 1998.
29. Fong HH. Integration of herbal medicine into modern medical practices: Issues and prospects. Integr Cancer Ther. 2002; 1: 287-93.
30. World Health Organization. WHO Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants. Geneva: World Health Organization; 2003a.
31. World Health Organization. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine. WHO/EDM/.TRM/2000.1. Geneva: World Health Organization; 2000b.
32. World Health Organization. Legal Status of Traditional Medicine and Complementary/Alternative Medicine: A Worldwide Review. WHO/EDM/TRM/2001. Geneva: World Health Organization; 2001.
33. World Health Organization. Traditional and Modern Medicine, Harmonizing the Two Approaches. Manila: World Health Organization, Western Pacific Region; 2000a.
34. World Health Organization. Guidelines for the regulation of herbal medicines in the South-East Asia Region. New Delhi: Regional Office for South-East Asia; 2003b.
35. Skalli S, Soulaymani Bencheikh R. Safety monitoring of herb-drug interactions: A component of pharmacovigilance. Drug Saf. 2012; 35: 785-91.
36. Shetti S, Kumar CD, Sriwastava NK, Sharma IP. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014; 4: 177.
37. World Health Organization. Guidelines on minimum requirements for the registration of herbal medicinal products in the Eastern Mediterranean Region. Cairo: World Health Organization (WHO), Regional Office for the Eastern Mediterranean; 2006.
38. Development of Traditional Medicine in the South-East Asia Region. Report of a Regional Consultative Meeting Pyongyang, DPR Korea. World Health Organization, Regional office for South East Asia New Delhi; November, 2005.
39. Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: A randomized controlled trial. JAMA. 1998; 280: 1585-9.
40. McCrindle BW, Helden E, Conner WT. Garlic extract therapy in children with hypercholesterolemia. Arch Pediatr Adolesc Med. 1998; 152: 1089-94.
41. Wambebe C, Khamofu H, Momoh JA, Ekpeyong M, Audu BS, Njoku OS, et al. Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN in patients with sickle cell disorder. Phytomedicine. 2001; 8: 252-61.
42. Zhang G, Zhao J, He L, Yan S, Zhuo Z, Zheng H, et al. Reduning injection for fever, rash, and ulcers in children with mild hand, foot, and mouth disease: A randomized controlled clinical study. J Tradit Chin Med. 2013; 33: 733-42.
43. Lian F, Li G, Chen X, Wang X, Piao C, Wang J, et al. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: A double-blind, randomized, placebo-controlled, multicenter trial. J Clin Endocrinol Metab. 2014; 99: 648-55.
44. Gertsch JH, Basnyat B, Johnson EW, Onopa J, Holck PS. Randomised, double blind, placebo controlled comparison of Ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: The prevention of high altitude illness trial (PHAIT). BMJ. 2004; 328: 797.
45. Tao X, Younger J, Fan FZ, Wang B, Lipsky PE. Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: A double-blind, placebo-controlled study. Arthritis Rheum. 2002; 46: 1735-43.